liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Högberg, Thomas
Publications (10 of 14) Show all publications
M Del Campo, J., Roszak, A., Bidzinski, M., Ciuleanu, T. E., Högberg, T., Wojtukiewicz, M. Z., . . . Lebedinsky, C. (2009). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. ANNALS OF ONCOLOGY, 20(11), 1794-1802
Open this publication in new window or tab >>Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Show others...
2009 (English)In: ANNALS OF ONCOLOGY, ISSN 0923-7534, Vol. 20, no 11, p. 1794-1802Article in journal (Refereed) Published
Abstract [en]

Patients and methods: Patients previously treated with less than two or two previous chemotherapy lines were randomized to receive trabectedin 1.5 mg/m(2) 24 h (arm A, n = 54) or 1.3 mg/m(2) 3 h (arm B, n = 53). Objective response rate (ORR) per RECIST was the primary efficacy end point. Toxic effects were graded according to the National Cancer Institute-Common Toxicity Criteria v. 2.0. Results: ORR was 38.9% [95% confidence interval (CI) 25.9% to 53.1%; arm A] and 35.8% (95% CI 23.1% to 50.2%; arm B) (intention-to-treat primary analysis). Median time to progression was 6.2 months (95% CI 5.3-8.6 months; arm A) and 6.8 months (95% CI 4.6-7.4 months; arm B). Frequent severe adverse events were nausea/vomiting (24%, arm A; 15%, arm B) and fatigue (15%, arm A; 10%, arm B). Common severe laboratory abnormalities were transient, noncumulative neutropenia (55%, arm A; 37%, arm B) and transaminase increases (alanine aminotransferase, 55%, arm A; 59%, arm B). Conclusions: Both every-3-weeks trabectedin regimes, 1.5 mg/m(2) 24 h and 1.3 mg/m(2) 3 h, were active and reasonably well tolerated in AOC platinum-sensitive patients. Trabectedin every-3-weeks has promising activity and deserves to be further evaluated in relapsed AOC.

Keywords
ovarian cancer, phase II, RECIST, response rate, trabectedin
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-51784 (URN)10.1093/annonc/mdp198 (DOI)
Available from: 2009-11-18 Created: 2009-11-17 Last updated: 2009-11-18
du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., . . . Wagner, U. (2005). 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology, 16(supplement 8), 36-38
Open this publication in new window or tab >>2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Show others...
2005 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 16, no supplement 8, p. 36-38Article in journal (Refereed) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-33462 (URN)19483 (Local ID)19483 (Archive number)19483 (OAI)
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2017-12-13
Stuart, G., Åvall-Lundqvist, E., du Bois, A., Bookman, M., Bowtell, D., Brady, M., . . . Wagner, U. (2005). 3rd international ovarian cancer consensus conference: outstanding issues for future consideration. Annals of Oncology, 16(supplement 8), viii36-viii38
Open this publication in new window or tab >>3rd international ovarian cancer consensus conference: outstanding issues for future consideration
Show others...
2005 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 16, no supplement 8, p. viii36-viii38Article in journal (Refereed) Published
Place, publisher, year, edition, pages
Oxford University Press, 2005
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-33461 (URN)10.1093/annonc/mdi965 (DOI)000232822800006 ()2-s2.0-27744543123 (Scopus ID)19482 (Local ID)19482 (Archive number)19482 (OAI)
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2017-04-21Bibliographically approved
Vermorken, J., Parmar, M., Brady, M., Eisenhauer, E., Högberg, T., Ozols, R., . . . Verheijen, R. (2005). Clinical trials in ovarian carcinoma: study methodology. Annals of Oncology, 16(S8), 20-29
Open this publication in new window or tab >>Clinical trials in ovarian carcinoma: study methodology
Show others...
2005 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 16, no S8, p. 20-29Article in journal (Refereed) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-33332 (URN)19343 (Local ID)19343 (Archive number)19343 (OAI)
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2017-12-13
Högberg, T., Fredstorp-Lidebring, M., Alm, P., Baldetorp, B., Larsson, G., Ottosen, C., . . . Lindahl, B. (2004). A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. International Journal of Gynecological Cancer, 14(3), 437-450
Open this publication in new window or tab >>A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer
Show others...
2004 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 14, no 3, p. 437-450Article in journal (Refereed) Published
Abstract [en]

A management program for FIGO stage I-II nonserous, nonclear-cell adenocarcinomas was evaluated. Histopathology and DNA ploidy were used to estimate postoperatively the risk of progression or death of disease and to tailor treatment. The patient material was a population-based consecutive cohort of all women with endometrial cancer in the Southern Swedish Health Care Region diagnosed between June 1993 and June 1996 (n=553). Of these, 335 were eligible for the management program. Patients estimated to be at low risk were treated by surgery only, while high-risk patients also received vaginal brachytherapy. A large low-risk group consisting of 84% (n=283) of the patients with an estimated disease-specific 5-year survival of 96% (95% CI=93-98%) was identified. The high-risk group (n=52, 16%) showed a worse outcome with an 80% 5-year disease-specific survival (95% CI=65-89%). The difference in survival between the groups was highly significant (P<0.0001). Half of the progressions were distant in the high-risk group. Although there is a clear indication for adjuvant therapy for this group, locoregional radiotherapy could be expected to fail in cases with distant progression. Thus, effective systemic treatments need to be developed. Low-risk patients, constituting the majority (84%) of the patients, can be safely treated by surgery only.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-23585 (URN)10.1111/j.1048-891x.2004.014303.x (DOI)3070 (Local ID)3070 (Archive number)3070 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Tropé, C., Nordal, R., Himmelmann, A., Kjörstad, K., Onsrud, M., Simonsen, E., . . . Svanberg, L. (2003). Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. International Journal of Gynecological Cancer, 13, 278-286
Open this publication in new window or tab >>Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment
Show others...
2003 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 13, p. 278-286Article in journal (Refereed) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-25101 (URN)9533 (Local ID)9533 (Archive number)9533 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Nordengren, J., Fredstorp Lidebring, M., Bendahl, P.-O., Brunner, N., Fero, M., Högberg, T., . . . Casslén, B. (2002). High tumor tissue concentration of plasminogen activator inhibitor-2 (PAI-2) is an independent marker for shorter progression-free survival of patients with early stage endometrial cancer. International Journal of Cancer, 97, 379-385
Open this publication in new window or tab >>High tumor tissue concentration of plasminogen activator inhibitor-2 (PAI-2) is an independent marker for shorter progression-free survival of patients with early stage endometrial cancer
Show others...
2002 (English)In: International Journal of Cancer, ISSN 0020-7136, E-ISSN 1097-0215, Vol. 97, p. 379-385Article in journal (Refereed) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-25102 (URN)9534 (Local ID)9534 (Archive number)9534 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Taube, A. & Högberg, T. (2002). Med P: n som i "programpaket" - om studier av prognostiska faktorer. Läkartidningen, 99, 3302-3305
Open this publication in new window or tab >>Med P: n som i "programpaket" - om studier av prognostiska faktorer
2002 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 99, p. 3302-3305Article in journal (Other academic) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-25477 (URN)9923 (Local ID)9923 (Archive number)9923 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Högberg, T. & Rosenberg, P. (2002). Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Critical reviews in oncology/hematology, 44(SUPPL.)
Open this publication in new window or tab >>Role of weekly paclitaxel in the treatment of advanced ovarian cancer
2002 (English)In: Critical reviews in oncology/hematology, ISSN 1040-8428, E-ISSN 1879-0461, Vol. 44, no SUPPL.Article in journal (Refereed) Published
Abstract [en]

Dose-dense weekly administration of paclitaxel has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic paclitaxel concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard paclitaxel 3-weekly administration. Clinical studies have confirmed that paclitaxel can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of paclitaxel also appears to be better tolerated than 3-weekly administration. Single-agent weekly paclitaxel is associated with response rates of 20-65%. Combination therapy with weekly paclitaxel has mainly involved carboplatin and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan, and carboplatin plus doxorubicin. In an attempt to avoid problems with high corticosteroid doses, dexamethasone doses of 10 and 8 mg have been used successfully in premedication regimens for weekly paclitaxel in ovarian cancer. ⌐ 2002 Elsevier Science Ireland Ltd. All rights reserved.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-25104 (URN)9536 (Local ID)9536 (Archive number)9536 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Koul, A., Bendahl, P.-O., Borg, Å., Fernö, M., Fredstorp Lidebring, M., Högberg, T., . . . Willén, R. (2002). TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. International Journal of Gynecological Cancer, 12(4), 362-371
Open this publication in new window or tab >>TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer
Show others...
2002 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 12, no 4, p. 362-371Article in journal (Refereed) Published
Abstract [en]

Mutations in the TP53 tumor suppressor gene have been shown to significantly correlate with poor prognosis in endometrial cancer. In the present study we have evaluated a luminometric immunoassay (LIA) for quantitative estimation of TP53 protein expression in 65 cytosol preparations from endometrial cancer, previously analyzed for mutations in TP53 exons 4-10. LIA showed high (= 0.6 ng/mg protein) expression of TP53 protein in all eight tumors with missense mutation, but high protein levels were also detected in 15 tumors with normal TP53 sequence. All four tumors with nonsense or frameshift mutations had low or no TP53 protein expression. LIA was further evaluated in a retrospective study of 201 cytosol samples from endometrial cancer. TP53 overexpression (>= 0.6 ng/mg protein) was observed in 22% of the tumors and correlated with nonendometrioid histology types (P = 0.005), poorly differentiated tumors (P = 0.001), higher FIGO grade (P = 0.001), DNA nondiploidy (P = 0.002), and high S-phase fraction (P = 0.03). After a median follow-up time of 6.8 years (range 0.7-9.9 years), 22 (13%) progressions were observed in the 175 patients with early stage (I-II) disease. TP53 overexpression (P = 0.04), FIGO grade 3 vs. 1 + 2 (P = 0.01), higher age (P = 0.02), and DNA nondiploidy (P < 0.001) showed significant correlation to shorter progression-free survival in these patients. We conclude that TP53 protein analysis by LIA provides an incomplete correlation to mutation status and cannot substitute for mutation analysis in assessment of prognosis in endometrial carcinoma. In comparison to TP53 overexpression and higher FIGO grades, DNA nonploidy status seems to be a better prognostic indicator to define a subset of early stage endometrial cancer patients who may benefit by adjuvant chemotherapy/radiotherapy.

National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-25103 (URN)10.1046/j.1525-1438.2002.01111.x (DOI)9535 (Local ID)9535 (Archive number)9535 (OAI)
Available from: 2009-10-07 Created: 2009-10-07 Last updated: 2017-12-13
Organisations

Search in DiVA

Show all publications